Clinicians must exhaust all diagnostic options (biopsy, MRI, PET CT) to confirm if esophageal cancer has metastasized. Assuming metastasis without certainty is a critical error, as it closes the door on potentially curative treatments for what might be localized disease.
While multidisciplinary care remains vital, the traditional team of surgery, radiation oncology, and medical oncology is evolving for adenocarcinoma. With radiation therapy being "sidelined" for these patients, care planning now often simplifies to a collaboration between just medical oncology and surgery.
New targeted therapies are often approved only for first-line use. This forces clinicians into a difficult choice: using one effective drug like a checkpoint inhibitor means forfeiting the chance to use another, like zolbetuximab, in a subsequent line of treatment, thereby losing a valuable therapeutic option.